A new cytogenetic approach for the evaluation of mutagenic potential of chemicals that induce cell cycle arrest in the G2 phase.
The aim of the present study was to develop and standardize a cytogenetic approach for evaluation of the mutagenic potential of chemicals that induce cell cycle arrest in the G2 phase. Even though cytogenetic end-points such as sister chromatid exchange (SCE) have been extensively used to indirectly assess the DNA-damaging potential of various chemicals, they are based on metaphase chromosome analysis. Cells delayed in G2 phase after chemical exposure are not included in conventional SCE analysis. The yield of SCEs obtained, therefore, can be biased, since predominantly undamaged cells proceed to metaphase without delay. To overcome this shortcoming of conventional SCE analysis, the use of a new cytogenetic approach for genotoxic studies is presented that enables the analysis of SCEs directly in G2 phase using drug-induced premature chromosome condensation in cultured peripheral blood lymphocytes. By means of this method, firstly, the possibility that SCE analysis in metaphase chromosomes underestimates the mutagenic potential of various chemicals was tested. Secondly, whether the genotoxic potential of suspected carcinogens could be evaluated using SCE analysis in G2 phase, even at exposures that arrest cells in G2 phase, was examined. Thirdly, whether an important part of the background variation in SCE frequency among individuals is due to the delay of affected cells in G2 phase, rather than to a true biological variation in the cytogenetic end-point used, was tested. The results showed that a higher SCE frequency was scored in G2 phase than in metaphase. Subsequently, the mutagenic potential of chemicals that temporarily arrest cells in G2 phase could now be evaluated more accurately. In addition, it may be of interest to further examine the involvement of cell cycle kinetics in the baseline SCE variation among individuals since a lesser SCE variability was observed when the analysis was carried out in G2 phase rather than at metaphase.
Terzoudi
G I
GI
Health Physics and Environmental Hygiene, National Centre for Scientific Research, Agia Paraskevi, Athens, Greece. georgia@ipta.demokritos.gr
Malik
S I
SI
Pantelias
G E
GE
Margaritis
K
K
Manola
K
K
Makropoulos
W
W
D001973:Bromodeoxyuridine; D002273:Carcinogens / Q000494:pharmacology*; D002869:Chromosome Aberrations; D002875:Chromosomes / Q000187:drug effects* / Q000235:genetics; D016195:G2 Phase / Q000187:drug effects*; D006801:Humans; D008214:Lymphocytes / Q000097:blood / Q000187:drug effects; D008387:Marine Toxins; D008677:Metaphase; D008938:Mitosis / Q000187:drug effects; D016296:Mutagenesis; D010080:Oxazoles / Q000494:pharmacology*; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors; D012854:Sister Chromatid Exchange / Q000187:drug effects
D002273:Carcinogens; D008387:Marine Toxins; D010080:Oxazoles; C059041:calyculin A; D010749:Phosphoprotein Phosphatases; D001973:Bromodeoxyuridine